| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | TPST-1495 (novel dual receptor inhibitor of prostaglandin signaling) Familial Adenomatous Polyposis (FAP) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System | |
Phase 2 data readout example | TPST-1495 (novel dual receptor inhibitor of prostaglandin signaling) Familial Adenomatous Polyposis (FAP) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System | |
Phase 2 data readout example | TPST-1495 (novel dual receptor inhibitor of prostaglandin signaling) Familial Adenomatous Polyposis (FAP) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System |
Recent Updates
Recently added Catalysts
Tempest Therapeutics, Inc.
$1.1
+0.05 (+4.81%)
D 25Pipeline Score Richly Valued Pharma · Clinical
Market Cap
17.58 M
EPS
-2.53
P/E Ratio
-
Value Trade
465.93 K
2.8 %
Week
17.7 %
1 Month
-37.85 %
3 Month
-55.82 %
6 Month
-99.13 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
201.24 K
52 Week Range
0.84 - 6.12
% held by Insiders
39.64 %
% held by Institutions
6.67 %
Enterprise Value
16.80 M
Total Shares
15.98 M
Short %
2.77 %
Float Shares
8.97 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tempest Therapeutics, Inc.
585Total events
22Upcoming
115Tier-1 (high impact)
2012 – 2027Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T2IND Submission
Subscribe to view catalyst details
Event history 2
TBD
▲Partnership / LicenseCorporate
Subscribe to view catalyst details
TBD
▲Partnership / LicenseTPST-4003Corporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-12-31 | TPST-1495 | Phase 1 data readout | Phase 1 | — | – | – | – |
2024-12-31 | TPST-1495 | Phase 1 data readout | Phase 1 | — | – | – | – |
2024-12-31 | TPST-1495 | Phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
D25
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 25%
Micro Cap (rank 701 of 933)
Percentile RankTempest Therapeutics, Inc. faces pipeline headwinds (25/100), with $369M risk-adjusted pipeline value, led by ATR-101 in Adrenocortical Carcinoma (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATR-101 Small molecule | Congenital Adrenal Hyperplasia | Phase 2 | NCT02804178 | 7% | $190M | COMPLETED | 10 | - | - | Aug 17, 2017 | - | Mar 10, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TPST-2003 | relapsed/refractory multiple myeloma | Phase 1/2a | 2026-05-14 | 100%; 15; no Grade 3 cytokine release syndrome; no immune effector cell-associated neurotoxicity syndrome; 23.1 months Read More | Tempest Reports First Quarter 2026 Financial Results and Provides Business Update Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myel Read More | |
TPST-2003 | relapsed/refractory multiple myeloma | Phase 1/2a | 2026-05-14 | 100%; 15; no Grade 3 cytokine release syndrome; no immune effector cell-associated neurotoxicity syndrome; 23.1 months Read More | Tempest Reports First Quarter 2026 Financial Results and Provides Business Update Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myel Read More | |
TPST-2003 | relapsed/refractory multiple myeloma | Phase 1/2a | 2026-05-14 | 100%; 15; no Grade 3 cytokine release syndrome; no immune effector cell-associated neurotoxicity syndrome; 23.1 months Read More | Tempest Reports First Quarter 2026 Financial Results and Provides Business Update Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myel Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TPST
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TPST Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TPST▼ -13.2%on this news
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Tempest has reported its financial results for Q2 2026 and announced a collaboration with Senlang Biotechnology. This partnership aims to advance the development of TPST-4003, a next-generation CAR-T therapy targeting CD7. The first patient is expected to be dosed in the fourth quarter of 2026, with initial clinical data anticipated shortly thereafter.
Read more →TPSTTempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
Tempest Therapeutics has announced a collaboration with Senlang Biotechnology to develop TPST-4003, a next-generation in vivo CAR-T therapy targeting CD7. The partnership aims to initiate a first-in-human trial in patients with neurological autoimmune diseases, including myasthenia gravis and multiple sclerosis, with dosing expected in late 2026. This collaboration is seen as a significant step towards advancing innovative CAR-T therapies.
Read more →TPST▲ +9.1%on this news
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
Tempest Therapeutics has announced its next-generation in vivo CAR-T pipeline, focusing on the lead candidate TPST-4003. This candidate combines a CD7-targeted mRNA delivery system with a dual-targeting CAR architecture aimed at treating autoimmune diseases like myasthenia gravis and multiple sclerosis. The first clinical trial is set to begin in Q4 2026, with initial data expected in 2027.
Read more →TPSTTempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors Brisbane, CA
Tempest Therapeutics has appointed Drake Richey and John Yee, MD, MPH, to its Board of Directors as of June 4, 2026. Both appointees bring extensive experience in their respective fields, with Richey specializing in corporate finance and Yee in medical affairs. The company's President and CEO, Dr. Matt Angel, expressed optimism about how their expertise could contribute to Tempest's goal of providing innovative cancer treatment options. This move aligns with the company's focus on growth and strategic capital allocation in the therapeutic landscape.
Read more →TPST▼ -11.6%on this news· ran to -27% by day 3
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
Tempest Therapeutics has announced the immediate exercise of outstanding warrants, generating approximately $2 million in gross proceeds. The company will issue new short-term warrants that could yield an additional $4 million if fully exercised. The transaction is subject to customary closing conditions and aims to support working capital and corporate purposes.
Read more →TPST▲ +13.6%on this news
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myel
Tempest Therapeutics reported positive interim results from the REDEEM-1 Phase 1/2a trial of TPST-2003 for relapsed/refractory multiple myeloma, achieving a complete response rate of 100% among evaluable patients. The company appointed Andrew Fang, Ph.D., as the new Head of Business Development and announced Cincinnati Children's AGCTC as their lead manufacturing partner. Despite advancements, Tempest reported a significant increase in net losses and a decline in cash reserves compared to the previous year. The company is planning a registrational study for TPST-2003 and seeking strategic partnerships.
Read more →TPST▼ -6%on this news
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
Tempest Therapeutics presented promising clinical data for TPST-2003 at the ISCT 2026 Annual Meeting. The therapy achieved a 100% complete response rate among CAR-T-naïve patients in two Phase 1 trials, demonstrating a favorable safety profile. The results suggest that TPST-2003 could be a leading treatment option for relapsed/refractory multiple myeloma, especially in patients with extramedullary disease.
Read more →TPSTTempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
Tempest Therapeutics will present new clinical data for its dual-targeting CAR-T therapy, TPST-2003, at the ISCT Annual Meeting in May 2026. The latest results from the REDEEM-1 Phase 1/2a trial show a 100% complete response rate among evaluable patients. The therapy aims to enhance treatment outcomes for patients with relapsed/refractory multiple myeloma, particularly those with extramedullary disease.
Read more →TPSTTempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
Tempest Therapeutics has reached a significant milestone in the development of TPST-2003, a dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma. The delivery of the lentiviral vector to Cincinnati Children's AGCTC enables the initiation of pivotal studies planned for late 2026. Interim data from the REDEEM-1 trial shows a 100% complete response rate among efficacy evaluable patients, highlighting the therapy's potential.
Read more →TPST▲ +5.1%on this news
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
Tempest Therapeutics has appointed Andrew Fang, Ph.D., as Head of Business Development to enhance its strategic partnerships and global licensing efforts. Dr. Fang will focus on expanding outreach in China and advancing discussions for the Phase 3-ready amezalpat program. This appointment reflects Tempest's commitment to business development as a core strategic priority.
Read more →TPST▼ -12.1%on this news
Tempest Reports Year End 2025 Financial Results and Provides Business Update
Tempest Therapeutics reported its financial results for 2025, highlighting a strategic acquisition of CAR-T assets and positive interim data from the REDEEM-1 trial of TPST-2003 for relapsed/refractory multiple myeloma. The company aims to initiate a U.S. registrational study for TPST-2003 later this year. Despite a decrease in cash reserves and an increase in net loss, the company remains optimistic about its pipeline and future milestones.
Read more →TPST▼ -19.7%on this news
Tempest Therapeutics Announces Up To $6 Million Private Placement
Tempest Therapeutics has announced a private placement to raise up to $6 million through the sale of shares and warrants. The offering, which is expected to close on March 23, 2026, will provide funds for working capital and corporate purposes. However, the company faces uncertainties regarding the exercise of warrants and market conditions.
Read more →TPSTTempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
Tempest Therapeutics announced a partnership with Cincinnati Children's Applied Gene and Cell Therapy Center for the development of TPST-2003, a CD19/BCMA dual-targeting CAR-T therapy aimed at treating relapsed/refractory multiple myeloma. The partnership includes tech transfer and IND-enabling manufacturing, with activities expected to complete by Q3 2026. TPST-2003 has shown promising results in the ongoing REDEEM-1 trial, achieving a complete response in all six efficacy evaluable patients as of January 31, 2026. This positioning may present TPST-2003 as a potential leading therapy in its field, subject to FDA approval.
Read more →TPST▼ -6.4%on this news
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
Tempest Therapeutics announced promising interim results from the REDEEM-1 trial of TPST-2003, a dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma. All evaluable patients achieved a complete response, and the therapy demonstrated a favorable safety profile. Tempest plans to present further results and initiate a U.S. registrational study in 2026.
Read more →TPSTTempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
Tempest Therapeutics has outlined its strategic plan to advance its newly acquired dual-targeting CAR-T assets, focusing on the TPST-2003 program. The company aims to maintain a capital-efficient operation while exploring next-generation CAR-T modalities. CEO Dr. Matt Angel emphasized leveraging partner-funded development to generate valuable clinical data without significant internal capital commitment.
Read more →TPSTAccelerating the Development of Advanced Therapies for Cancer Patients February 2026 Forward Looking Statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Se
Tempest Therapeutics, Inc. has provided an update on its progress in developing advanced cancer therapies. The company is actively working on an expanded oncology pipeline that includes several initiatives currently in clinical trials. Notably, TPST-2003, a dual-target CAR-T cell therapy, has demonstrated promising results in initial studies, prompting plans for a BLA submission in China by 2027. However, the company cautions that forward-looking statements reflect uncertainties that may affect its future performance and product development.
Read more →TPST▼ -6.3%on this news
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
Tempest Therapeutics has successfully closed its acquisition of dual-targeting CAR-T assets from Factor Bioscience, enhancing its pipeline of cancer therapies. This all-stock transaction provides Tempest with financial stability and the potential for significant milestones over the next 12-18 months. The company aims to develop innovative therapies for solid tumors and hematologic malignancies.
Read more →TPSTTempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
Tempest Therapeutics has announced a record date of January 30, 2026, for the distribution of warrants to purchase common stock as a dividend. The warrant dividends are expected to be distributed on February 3, 2026, contingent upon the satisfaction of closing conditions, including stockholder approval. The company is focused on developing targeted and immune-mediated cancer therapeutics.
Read more →TPSTTempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
Tempest Therapeutics has successfully closed a registered direct offering of 1,172,414 shares at $3.625 each, generating approximately $4.25 million in gross proceeds. Additionally, the company issued short-term unregistered warrants that could provide up to $4.1 million more if exercised. The funds will primarily be used for working capital and corporate purposes.
Read more →TPST▼ -23.3%on this newsshared move
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
Tempest Therapeutics has announced a registered direct offering of common stock, aiming to raise up to $8.35 million. The offering includes the sale of 1,172,414 shares at $3.625 each, alongside a concurrent private placement of warrants. The proceeds will primarily support working capital and corporate needs, with the closing expected shortly, pending customary conditions.
Read more →TPST▼ -48.6%on this news· ran to -60% by day 1
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
Tempest Therapeutics has announced a strategic acquisition of dual-CAR T programs from Factor Bioscience, aiming to diversify its pipeline and extend its operational runway to mid-2027. The transaction is set to close in early 2026, pending stockholder approval. This acquisition includes the first clinical-stage dual-CAR T targeting extramedullary disease, enhancing Tempest's therapeutic offerings.
Read more →TPST▲ +9.1%on this news
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update
Tempest Therapeutics reported its financial results for Q3 2025 and provided a business update. The company is focused on maximizing shareholder value through strategic alternatives and is optimistic about the upcoming Phase 2 trial of TPST-1495 in collaboration with the NCI. The CEO expressed confidence in the therapeutic potential of amezalpat for first-line HCC treatment.
Read more →TPST▲ +8.8%on this news· ran to +29% by day 3
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update • Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC)
Tempest Therapeutics reported its financial results for Q2 2025, highlighting key advancements in its clinical portfolio. The company received clearance to initiate a pivotal trial for amezalpat in China and was granted orphan drug designations for both amezalpat and TPST-1495. Despite a strengthened cash position from a direct offering, Tempest's net losses increased, and cash reserves saw a significant decline compared to the previous year. The company remains focused on maximizing value for stockholders through strategic alternatives.
Read more →TPSTTempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
Tempest Therapeutics has received clearance from China's NMPA to initiate a pivotal trial for amezalpat in combination with atezolizumab and bevacizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC). This trial aims to evaluate the efficacy of the combination therapy against the standard of care. The approval marks a significant step towards addressing the high prevalence of HCC in global markets.
Read more →TPST▼ -15.9%on this news
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
Tempest Therapeutics has announced a registered direct offering of 739,000 shares of common stock at $6.25 per share, aiming to raise approximately $4.6 million. The funds will primarily support strategic alternatives and general corporate purposes. The offering is expected to close around June 12, 2025, pending customary conditions.
Read more →TPST▲ +15.2%on this news· ran to +29% by day 3
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
Tempest Therapeutics has received Orphan Drug Designation from the EMA for amezalpat, a selective PPARα antagonist aimed at treating hepatocellular carcinoma (HCC). This designation follows similar support from the FDA and is based on positive clinical trial results showing improved overall survival rates. Amezalpat targets tumor cells and modulates immune responses, indicating its potential effectiveness in addressing unmet needs in liver cancer treatment.
Read more →TPSTTempest Reports First Quarter 2025 Financial Results and Provides Business Update • Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual Me
Tempest Therapeutics, Inc. (TPST) reported its financial results for Q1 2025, highlighting its progress in cancer treatment development. The company's amezalpat program presented promising new data at the 2025 AACR Annual Meeting, with significant FDA designations granted for both amezalpat and TPST-1495 treatments. Despite these advancements, Tempest reported a net loss of $10.9 million and a decrease in cash reserves compared to the previous quarter. The company also plans to explore strategic alternatives to enhance stockholder value.
Read more →TPST▼ -6.3%on this news
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
Tempest Therapeutics presented new data on amezalpat at the 2025 AACR Annual Meeting, highlighting its immune-mediated mechanism of action. The data indicate that amezalpat reduces tumor-promoting immunosuppression, showing potential as a novel cancer treatment. Clinical trials have demonstrated its efficacy in patients with hepatocellular carcinoma, renal cell carcinoma, and cholangiocarcinoma, particularly in combination with approved therapies.
Read more →TPSTTempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
Tempest Therapeutics has announced that the FDA granted Orphan Drug Designation to TPST-1495 for treating Familial Adenomatous Polyposis (FAP). This designation is a significant milestone for the company, which aims to provide innovative therapies for patients with unmet medical needs. A Phase 2 study for TPST-1495 is expected to commence this year, with results anticipated in 2026.
Read more →TPST▼ -18%on this news
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
Tempest Therapeutics plans to explore strategic alternatives to enhance its clinical oncology pipeline and maximize shareholder value. The company is considering various options, including mergers and partnerships, and has engaged MTS Health Partners for support. Despite positive data from its amezalpat Phase 2 study, current capital market conditions pose challenges for advancement.
Read more →TPSTTempest Reports Year End 2024 Financial Results and Provides Business Update • Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcino
Tempest Therapeutics announced its year-end financial results for 2024, highlighting significant achievements including achieving Orphan Drug and Fast Track designations for Amezalpat (TPST-1120) in the treatment of Hepatocellular Carcinoma. The company secured an agreement with Roche to advance Amezalpat in pivotal trials and received FDA approval for a Phase 2 trial of TPST-1495 for Familial Adenomatous Polyposis. Despite successful advancements and positive clinical data, Tempest reported a net loss of $41.8 million, reflecting increased operational costs.
Read more →TPSTTempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Tempest Therapeutics announced that an abstract on amezalpat, a PPARα antagonist, has been accepted for poster presentation at the 2025 AACR Annual Meeting. The presentation will focus on the immune component of amezalpat's mechanism of action. Scheduled for April 28, 2025, the session aims to explore the interplay between the immune system and cancer therapies. This opportunity showcases Tempest's ongoing contributions to cancer treatment research and development.
Read more →TPSTTempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Tempest Therapeutics has been granted Fast Track Designation by the U.S. FDA for its oral medication, amezalpat, aimed at treating hepatocellular carcinoma (HCC). This designation, along with a prior Orphan Drug designation, underscores the drug's potential to address significant unmet medical needs in HCC patients. Clinical trials have indicated that amezalpat, in combination with standard treatments, resulted in improved overall survival rates among patients. The company is optimistic about the further development and regulatory interactions surrounding this promising therapeutic candidate.
Read more →TPSTTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Therapeutics, Inc. has announced the granting of nonqualified stock options to one employee, allowing the purchase of 45,000 shares under its 2023 Inducement Plan. The options are set to vest over a four-year period, incentivizing continued employment. This move reflects the company’s strategy to foster investment in its innovative cancer therapies and highlights its ongoing commitment to developing its portfolio of tumor-targeted and immune-mediated treatments.
Read more →TPSTTempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
Tempest Therapeutics has been granted Orphan Drug Designation for its drug amezalpat by the U.S. FDA, aimed at treating hepatocellular carcinoma (HCC). This designation is notable given the challenges of treating HCC and the ongoing need for effective therapy. In clinical trials, amezalpat, when used in combination with standard therapies, has shown a significant improvement in patient outcomes, including overall survival rates. Tempest is now set to advance to a pivotal phase 3 study for this promising treatment.
Read more →TPSTTempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
Tempest Therapeutics, Inc. (Nasdaq: TPST) announced that its senior management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024. The conference will provide a platform for discussion about their targeted and immune-mediated therapeutics in cancer treatment. As a clinical-stage biotechnology company, Tempest is focused on advancing its diverse portfolio of small molecule product candidates. This engagement could be pivotal for attracting investor interest and showcasing their innovative approaches in oncology.
Read more →TPSTTempest Reports Third Quarter 2024 Financial Results and Provides Business Update - Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of am
Tempest Therapeutics reported its financial results for Q3 2024 and announced significant advancements in its clinical programs. The Company received a FDA 'Study May Proceed' letter to initiate a pivotal Phase 3 trial for amezalpat in combination with existing therapies for hepatocellular carcinoma. Additionally, Tempest has entered a partnership with Roche to advance this treatment and reported enhanced leadership to support its clinical initiatives. Despite these positive developments, the Company experienced a net loss and an increase in operational costs during the quarter.
Read more →TPSTTempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
Tempest Therapeutics, Inc. has announced that it received a 'Study May Proceed' letter from the FDA, allowing it to evaluate Amezalpat in combination with other standard treatments for first-line hepatocellular carcinoma (HCC) in a pivotal Phase 3 trial. The trial is designed to compare Amezalpat with the current standard of care. Positive results from earlier Phase 2 studies have fuelled optimism about Amezalpat's potential to enhance patient survival. The Phase 3 trial is set to begin in the first quarter of 2025.
Read more →TPST▼ -18.5%on this news
Tempest Extends Limited Duration Stockholder Rights Plan
Tempest Therapeutics has announced an amendment to extend its limited duration stockholder rights plan until the Annual Meeting of Stockholders. This move is aimed at protecting the company’s investors amid ongoing market volatility. The Board cited significant achievements in the amezalpat program and emphasized they believe the company's stock is undervalued. Notably, this extension is not a response to any specific takeover threat but is viewed as a protective measure for all shareholders. The rights plan remains effective unless approved by stockholders at the upcoming meeting in 2025.
Read more →TPST▼ -18.5%on this news
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
Tempest Therapeutics has announced an agreement with Roche to advance its therapy amezalpat into a pivotal Phase 3 trial for the treatment of unresectable or metastatic hepatocellular carcinoma. The agreement follows encouraging Phase 2 trial results that indicated a significant survival advantage for patients receiving amezalpat in combination with atezolizumab and bevacizumab. The FDA has also approved the study plan, allowing for an anticipated start of the Phase 3 trial in the first quarter of 2025. Tempest retains all rights for amezalpat and has expressed optimism regarding its potential in treating liver cancer.
Read more →TPSTTempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tempest Therapeutics, Inc. recently announced the granting of nonqualified stock options to two employees for a total of 79,500 shares under its 2023 Inducement Plan. These options will vest over four years, beginning with 25% on the first anniversary and subsequently on a monthly basis. This move underscores the company's strategy to align employee interests with its long-term goals and enhance retention. Tempest, a clinical-stage biotechnology company, focuses on developing innovative cancer therapeutics.
Read more →TPST▼ -6.6%on this newsshared move
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
Tempest Therapeutics has appointed Sheldon Mullins as Vice President of Regulatory Affairs, strengthening its leadership team. This move follows the addition of Troy Wagner as Vice President of Quality Assurance. The company is preparing to advance its candidate amezalpat into a pivotal study for hepatocellular carcinoma, reflecting its transition towards late-stage clinical development. Both Mullins and the extended team aim to enhance Tempest's capabilities and drive successful regulatory processes.
Read more →TPST▲ +5%on this news
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Tempest Therapeutics, a biotechnology company focusing on cancer therapies, announced that Dr. Sam Whiting will present at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available online starting September 9, 2024. Tempest is known for its development of targeted and immune-mediated therapeutics, with various programs ranging from early research to late-stage studies.
Read more →TPSTTempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
Tempest Therapeutics has announced the appointment of Troy M. Wagner as Vice President of Quality Assurance. With over 30 years of experience, Wagner's expertise is expected to enhance the company's operations as it advances towards Phase 3 development of its lead oncology candidate, amezalpat. The drug has shown promising clinical results in treating hepatocellular carcinoma. Wagner's previous roles in quality assurance across various pharmaceutical companies bolster her qualifications for this critical position.
Read more →TPST▲ +30.3%on this news
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
Tempest Therapeutics announced a successful end-of-Phase 2 meeting with the FDA regarding amezalpat (TPST-1120) for treating hepatocellular carcinoma. The FDA agreed on the pivotal Phase 3 study design, including endpoints and dosing schedules. A primary endpoint of overall survival from the Phase 2 trial was highlighted, and the early efficacy analysis may expedite results. The Phase 3 study is set to begin in Q1 2025, indicating strong anticipation for advancing this treatment.
Read more →TPSTTempest Reports Second Quarter 2024 Financial Results and Provides Business Update - Unveiled new positive survival data for amezalpat (TPST-1120) in randomized first-line hepatocellular carcinoma (“HCC)” s
Tempest Therapeutics reported its second quarter 2024 financial results, highlighting promising new survival data for amezalpat (TPST-1120) in treating hepatocellular carcinoma (HCC). The data demonstrate a six-month median survival advantage over the control arm, with a maintained hazard ratio indicative of consistent efficacy. The company plans to advance amezalpat towards a pivotal Phase 3 trial while also initiating a Phase 2 study for another drug, TPST-1495. Despite the positive clinical advancements, Tempest faced a net loss of $9.6 million, reflecting increased expenses and financial challenges.
Read more →TPST▼ -29.5%on this news
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm 21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40)
Tempest Therapeutics announced new data from a Phase 1b/2 clinical study evaluating amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab for patients with unresectable or metastatic hepatocellular carcinoma (HCC). The findings reveal a six-month increase in median overall survival for the amezalpat-treated patients compared to those receiving standard care. This enhances prior data showing significant benefits across various study endpoints and positions amezalpat favorably for a pivotal Phase 3 trial. The study involved 70 patients and was conducted in multiple global locations.
Read more →TPSTTempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
Tempest Therapeutics, a clinical-stage biotechnology company, announced plans to report new data from their Phase 1b/2 combination study of amezalpat (TPST-1120) with atezolizumab and bevacizumab in treating first-line hepatocellular carcinoma. The data will be revealed during a press release and subsequent webcast on June 20, 2024. This study represents an important step for Tempest in advancing its portfolio of cancer therapeutics.
Read more →TPSTTempest to Participate in Upcoming Investor Conferences
Tempest Therapeutics, Inc. (TPST) has announced its participation in two upcoming investor conferences. The company will engage in a fireside chat at TD Cowen's 5th Annual Oncology Innovation Summit on May 29 and will present at the Jefferies Global Healthcare Conference on June 5. These appearances highlight Tempest's ongoing commitment to advancing its portfolio of cancer therapies. Interested parties can access the discussions via the investor section of Tempest's website.
Read more →TPSTTempest Reports First Quarter 2024 Financial Results and Provides Business Update - Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAP - Reported new preclinical data f
Tempest Therapeutics recently reported its financial results for the first quarter of 2024, highlighting progress in its drug development pipeline. The company is advancing its candidate TPST-1120 into a pivotal Phase 3 trial for first-line hepatocellular carcinoma (HCC) and TPST-1495 into a Phase 2 trial for Familial Adenomatous Polyposis (FAP). Notably, positive preclinical and clinical data for TPST-1120 were presented at major oncology meetings, enhancing its potential in treating various cancers. However, financial performance reflected a net loss and a decrease in cash reserves compared to the previous quarter.
Read more →TPSTTempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
Tempest Therapeutics, Inc. reported new preclinical data for TPST-1120 at the AACR Annual Meeting, indicating a reduction in kidney cancer growth as a monotherapy and with combination therapies. The data revealed a tumor growth reduction of 52% to 56% when TPST-1120 was used alone and up to 81% when paired with standard treatments. The findings further validate prior Phase 1 clinical results and bolster the pipeline for advancing TPST-1120 into additional clinical studies, including pivotal trials in other cancer types. The drug demonstrates the potential to enhance the immune environment, supporting continued development for various oncology indications.
Read more →TPST▼ -12.2%on this news· ran to -27% by day 1shared move
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
Tempest Therapeutics announced the publication of positive clinical data from a Phase 1 trial of TPST-1120, an oral, selective PPARα antagonist, showing clinical activity in patients with advanced solid tumors, including those resistant to PD-1 inhibitors. The study demonstrated tumor shrinkage and was well tolerated, setting the stage for a pivotal Phase 3 trial in hepatocellular carcinoma (HCC). Notably, TPST-1120 showed efficacy in heavily pretreated cancer patients and had a clinical superiority over standard care in prior studies. The company is optimistic about the potential impact of TPST-1120 on cancer treatment outcomes.
Read more →TPSTTempest Reports Year End 2023 Financial Results and Provides Business Update - Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compar
Tempest Therapeutics reported strong year-end financial results for 2023, highlighting the success of TPST-1120 in clinical trials for first-line hepatocellular carcinoma (HCC). The company announced positive randomized data indicating superiority over standard care and plans to move forward with pivotal Phase 3 trials. Additionally, new biomarker data in specific subpopulations supports the efficacy of their therapies. Despite an increased net loss, Tempest maintains a solid cash position to fund operations into 2025.
Read more →TPSTTempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
Tempest Therapeutics presented new preclinical data at the SITC 2024 Spring Scientific Meeting regarding TPST-1120's anti-tumor effects across various cancer models. The data shows significant tumor growth inhibition, particularly in liver and colon cancers. Additionally, clinical biomarker results from a Phase 1 trial revealed elevated immune-related gene expression and favorable patient responses. The company's plans to advance toward pivotal studies in liver cancer were highlighted, showcasing the potential of TPST-1120's therapeutic strategy in addressing multiple cancer indications.
Read more →TPSTTempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
Tempest Therapeutics announced that collaborators at Beth Israel Deaconess Medical Center will present preclinical data on TPST-1120 for renal cell carcinoma at the AACR Annual Meeting from April 5-10, 2024. The poster presentation, scheduled for April 8, will focus on how the PPAR-α antagonist enhances immunotherapy and anti-angiogenic therapy to inhibit murine renal cancer. This news highlights the ongoing efforts in developing targeted cancer therapeutics.
Read more →TPSTTempest to Present at the 44th Annual TD Cowen Healthcare Conference
Tempest Therapeutics, Inc. (Nasdaq: TPST) announced that its CEO, Stephen Brady, will present at the 44th Annual TD Cowen Healthcare Conference on March 4, 2024. The focus of the presentation will be on the company's efforts to develop first-in-class targeted and immune-mediated therapeutics for cancer. Tempest is a clinical-stage biotechnology company based in Brisbane, California, with a diverse portfolio aimed at treating various tumors through novel mechanisms. Interested parties can access the presentation through the investor section of Tempest's website.
Read more →TPST▲ +9.2%on this news
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
Tempest Therapeutics, Inc. (Nasdaq: TPST) will present at the 35th Annual Piper Sandler Healthcare Conference on November 28, 2023. The company is focused on developing first-in-class oncology therapeutics that integrate both targeted and immune-mediated treatments. Key programs include TPST-1120 and TPST-1495, which are currently in trials aimed at evaluating their efficacy as monotherapies and in combination therapies. This event highlights Tempest's commitment to advancing innovative cancer treatments.
Read more →TPST▼ -8.7%on this news
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update - TPST-1120 demonstrates superiority compared to standard of care across multiple study endpoints in randomized first-line HCC study - New
Tempest Therapeutics reported promising third quarter 2023 financial results alongside positive updates on its clinical candidate TPST-1120, which demonstrated superiority against standard care for liver cancer. The company noted improved data in various study endpoints, including a significant increase in confirmed objective response rates. Additionally, Tempest announced plans to advance TPST-1120 into further studies, potentially in collaboration with partners, while strengthening its financial position with new capital. However, uncertainties remain regarding overall survival data, as it has not been reached for the TPST-1120 arm yet.
Read more →TPST▲ +3970.8%on this news
Tempest Adopts Limited Duration Stockholder Rights Plan
Tempest Therapeutics has announced the adoption of a limited duration stockholder rights plan to safeguard long-term shareholder interests amidst significant stock price dislocation. The Rights Plan allows stockholders to realize long-term value and prevent any party from gaining control through open market accumulation. This plan is not in direct response to a specific takeover threat and also includes features to facilitate future Board actions. Rights will be exercisable for a limited time based on certain ownership thresholds.
Read more →TPST▲ +3970.8%on this news
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study New data package reveals improvements in multiple categories for TPST-1120 combined
Tempest Therapeutics announced new data showing that its drug TPST-1120 exhibits clinical superiority in treating unresectable or metastatic hepatocellular carcinoma (HCC) when combined with atezolizumab and bevacizumab. The findings were based on a planned data analysis from an ongoing randomized Phase 1b/2 clinical study, which indicates improved outcomes for patients. This comprehensive analysis highlighted benefits that exceed those from earlier interim results, prompting Tempest to anticipate moving TPST-1120 into pivotal studies in collaboration with Roche, which managed the study operations.
Read more →TPSTTempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
Tempest Therapeutics, Inc. has announced plans to report new and updated data from its Phase 1b/2 global randomized combination study of TPST-1120, atezolizumab, and bevacizumab for the first-line treatment of hepatocellular carcinoma (HCC). The announcement includes a premarket press release scheduled for October 11, 2023, followed by a conference call at 8:30 a.m. ET. The company is advancing innovative therapies that aim to combine tumor-targeted and immune-mediated mechanisms for cancer treatment.
Read more →TPSTTempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
Tempest Therapeutics has announced that Dr. Sam Whiting will expand his responsibilities as Chief Medical Officer to also lead the Research and Development department. Dr. Whiting, who has experience in drug development and clinical oncology, aims to enhance collaboration between Tempest's R&D efforts and its clinical programs. The company is currently focusing on its lead program TPST-1120, which has shown promising early data in treating liver cancer. Tempest plans to further develop its robust pipeline of innovative therapeutics under Dr. Whiting's leadership.
Read more →TPSTTempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Tempest Therapeutics, Inc. (Nasdaq: TPST) announced that its Chief Medical Officer, Dr. Sam Whiting, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation aims to provide insights into the company's ongoing clinical programs for its oncology therapeutics. Tempest is developing small molecules aimed at treating various tumors, with promising early results from trials involving its lead candidates targeting liver and endometrial cancers. Details of the presentation will be available for on-demand viewing starting September 11, 2023.
Read more →TPST▲ +5.5%on this news
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update Brisbane, CA
Tempest Therapeutics reported its second quarter 2023 financial results, highlighting promising early data from its clinical programs TPST-1120 and TPST-1495. The company announced significant improvements in response rates for its TPST-1120 treatment in HCC patients, along with updates on its TPST-1495 program presented at the ASCO Annual Meeting. Despite this progress, Tempest's cash reserves declined to $17.6 million and it posted a net loss of $7.6 million for the quarter, raising concerns over its financial health. Upcoming milestones include further data reports from both programs expected in the near future.
Read more →TPSTTempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
Tempest Therapeutics has announced the publication of data in Cancer Research Communications regarding its drug TPST-1495, which shows enhanced anti-tumor potency by blocking the EP2 and EP4 receptors in prostaglandin E2 signaling. This unique mechanism provides a dual approach to inhibit tumor growth, supported by promising Phase 1 clinical findings demonstrating tumor shrinkage. The drug is currently being evaluated in combination with pembrolizumab for patients with advanced endometrial cancer. Furthermore, TPST-1495 poses potential applications across various cancers driven by PGE2 signaling.
Read more →TPST▼ -5.8%on this news
Tempest to Present at the Jefferies Global Healthcare Conference
Tempest Therapeutics, Inc. announced that it will present at the Jefferies Global Healthcare Conference on June 7, 2023. The company is focused on developing first-in-class oncology therapeutics that integrate targeted and immune-mediated approaches. Their portfolio includes novel programs such as TPST-1120 and TPST-1495, which are currently undergoing clinical trials. The presentation highlights Tempest's continued advancement in the clinical stage of oncology treatment.
Read more →TPSTTempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
Tempest Therapeutics, Inc. has announced promising Phase 1 trial results for TPST-1495, a novel dual receptor inhibitor, showcasing tumor shrinkage and disease control in advanced cancer patients. The data will be presented at the upcoming 2023 ASCO Annual Meeting. Patients treated with TPST-1495, both as a monotherapy and in conjunction with pembrolizumab, showed positive outcomes, including a durable partial response in a patient with microsatellite stable colorectal cancer. The safety profile of TPST-1495 was deemed acceptable and largely manageable, paving the way for further investigation in different cancer types.
Read more →TPSTTempest Reports First Quarter 2023 Financial Results and Provides Business Update Brisbane, CA
Tempest Therapeutics, Inc. reported its financial results for the first quarter of 2023, revealing a net loss of $7.6 million and a decrease in cash reserves to $22.9 million. The company presented promising early data for its lead product, TPST-1120, highlighting significant improvements in treatment responses for hepatocellular carcinoma patients. With multiple upcoming milestones, Tempest aims to sustain its operational viability through 2024 while navigating financial challenges.
Read more →TPST▲ +23.3%on this news
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma Positive randomized data with TPST-1120 combined with atezolizumab + bevaci
Tempest Therapeutics announced positive early results from a Phase 1b/2 study evaluating TPST-1120 in combination with atezolizumab and bevacizumab for treating first-line hepatocellular carcinoma (HCC). The study involved a randomized design with outcomes showing meaningful improvements in response rates compared to the standard therapy alone. The trial included data from a total of 70 patients, demonstrating promise for TPST-1120 as an active therapeutic option. Full data set presentations are expected later this year, which may provide more insights into efficacy and potential biomarkers.
Read more →TPSTTempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
Tempest Therapeutics, Inc. (Nasdaq: TPST) announced that it will report early results from its Phase 1b/2 combination study of TPST-1120 in first-line hepatocellular carcinoma on April 28, 2023. The announcement comes as the company continues to develop innovative oncology therapeutics that target tumors through both immune and targeted mechanisms. A conference call will be held alongside the release, providing updates and a platform for investor questions. The study is part of Tempest's broader portfolio of clinical programs aimed at improving treatment options for cancer patients.
Read more →TPST▼ -6.7%on this newsshared move
Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting
Tempest Therapeutics, Inc. has announced that an abstract on its drug TPST-1495 has been accepted for a poster presentation at the 2023 ASCO Annual Meeting in Chicago. The focus of the presentation will be a Phase 1 study examining TPST-1495 as a single agent and in combination with pembrolizumab for treating patients with advanced solid tumors. This highlights Tempest's continuing advancement of innovative cancer therapies.
Read more →TPST▲ +25.4%on this news
Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting
Tempest Therapeutics announced new data at the 2023 AACR Annual Meeting highlighting its TPST-1120 and TREX1 programs. The findings from a Phase 1 trial indicated significant biomarker changes dependent on drug exposure levels for patients treated with TPST-1120 and nivolumab. Additionally, the TREX1 inhibitor demonstrated potential in activating the STING pathway with promising results in preclinical models. The company aims for further clinical development of these candidates in advanced cancer therapies.
Read more →TPSTTEMPEST THERAPEUTICS, INC. Consolidated Statements of Operations (in thousands except per share amounts) Twelve months ended Twelve months ended
Tempest Therapeutics, Inc. reported significant milestones in its 2022 financial results and outlined upcoming projects. The company announced positive data from its TPST-1120 Phase 1 trial and confirmed the enrollment of its TPST-1120 combination study with Roche. They reported a net loss of $35.7 million for the year and a cash reserve decrease, prompting a focus on upcoming data and funding strategies. Tempest anticipates a data-rich year ahead with several trials and presentations scheduled for 2023.
Read more →TPSTTempest Reports Year End 2022 Financial Results and Provides Business Update
Tempest Therapeutics, Inc. reported its financial results for the year ended December 31, 2022, highlighting significant milestones in its clinical programs. The company showcased positive data from its TPST-1120 trial, including a 30% overall response rate among patients traditionally unresponsive to immunotherapy. Additionally, TPST-1495 continues to advance with ongoing trials, and new biomarker data for both programs is expected in 2023. However, Tempest's cash reserves decreased from the previous year, necessitating careful financial management ahead.
Read more →TPSTTempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting
Tempest Therapeutics, Inc. announced that Dr. Nathan Standifer will present biomarker data for their drug TPST-1120 at the SITC 2023 Spring Scientific Meeting. The findings from a Phase 1 trial suggest a relationship between clinical benefits and fatty acid oxidation perturbations. This presentation is set for March 16, 2023, in Denver and virtually. TPST-1120 is a selective PPAR-α antagonist that is part of Tempest's exploration of novel oncology therapeutics.
Read more →TPST▲ +15.8%on this newsshared move
Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting
Tempest Therapeutics announced it will present two abstracts at the 2023 AACR Annual Meeting in Orlando, Florida, taking place from April 14 to 19. The presentations will include biomarker data from their Phase 1 trial of TPST-1120, an oral selective PPARα antagonist, as well as preclinical data from a TREX1 inhibitor targeting the STING pathway. Both presentations are part of clinical research and experimental therapeutics sessions, underscoring the company's commitment to advancing oncology therapeutics.
Read more →TPSTTempest to Present at the Piper Sandler 34th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company focused on developing first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management
Read more →TPSTTempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer
TPST-1120 Late-breaking Poster Presentation at SITC Annual Meeting Second Poster Presentation Demonstrates that Dual Blockade of EP2 and EP4 PGE2 Receptors with TPST-1495 is an Optimal Approach for Drugging the Prostaglandin Pathway SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (G
Read more →TPST▼ -12.1%on this newsshared move
Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the
Read more →TPST▲ +8.7%on this news
Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of two pos
Read more →TPSTTempest to Present at Emerging Technologies for IO Targeting and Discovery Summit
Dara Burdette, Ph.D., Tempest Senior Director of Discovery Research, to Chair “New Approaches to Solid Tumor Targeting” Session Nicholas DeVito, M.D, Duke University School of Medicine, to present TPST-1495 preclinical data SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWS
Read more →TPST▲ +11.4%on this news
Tempest to Present at the H.C. Wainwright 24th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Stephen R. Brady, c
Read more →TPST▲ +15.8%on this news· ran to +28% by day 1
Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the
Read more →TPST▲ +11.9%on this news
Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference
SOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class¹ therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Tom Dubensky, Ph.D.,
Read more →TPSTTempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance TPST-1120 demonstrated monotherapy clinical benefit in patients with late-line advanced, poor-prognosis cancers where respon
Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance South San Francisco, CA, June 9, 2022 Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing therapies that combine both targeted and immune-mediated
Read more →TPST▼ -12.5%on this newsshared move
Tempest to Present at the Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will pres
Read more →TPSTTempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting RECIST responses observed in IO-refractory patients and in IO-resistant indications 3
Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting South San Francisco, CA, May 26, 2022 Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing therapies that c
Read more →TPST▲ +5.9%on this news
Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights Announced oral presentation of TPST-1120 Phase 1 monotherapy and combination therapy data at ASCO Presented positive preclinical data
Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights Announced oral presentation of TPST-1120 Phase 1 monotherapy and combination therapy data at ASCO Presented positive preclinical data for TPST-1495 at AACR Presented positive preclinical da
Read more →TPST▲ +30.1%on this news· ran to +63% by day 3
Tempest Announces Private Placement Financing of $15 Million South San Francisco, Calif.
Tempest Announces Private Placement Financing of $15 Million South San Francisco, Calif., April 27, 2022 (GLOBE NEWSWIRE) Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing novel therapeutics that combine both targeted and immune-mediated me
Read more →TPST▲ +30.1%on this news· ran to +63% by day 3
Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting
Oral presentation for TPST-1120 completed Phase 1 trial results Poster presentation for TPST-1495 trial in progress SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing therapeuti
Read more →TPSTTempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting
Anti-tumor data from systemic novel TREX1 inhibitors designed to activate the STING pathway selectively in tumors Additional data further supporting and differentiating TPST-1495, a clinical-stage dual EP2/4 prostaglandin receptor antagonist SOUTH SAN FRANCISCO, Calif., April 0
Read more →TPSTTempest Reports Year End 2021 Financial Results and Provides Corporate Highlights First clinical data presentation planned for ASCO TPST-1120 Phase 1 monotherapy and combination dose escalation and optimization arms TPST
Tempest Reports Year End 2021 Financial Results and Provides Corporate Highlights First clinical data presentation planned for ASCO TPST-1120 Phase 1 monotherapy and combination dose escalation and optimization arms TPST-1120 randomized study in first-line HCC patients with pa
Read more →TPST▼ -9.2%on this news
Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will pre
Read more →TPSTTempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced two poster presentations
Read more →TPSTTempest to Present at the 11th Annual SVB Leerink Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will pres
Read more →TPSTTempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab
Combination based on both strong mechanistic rationale and preclinical data SOUTH SAN FRANCISCO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both tu
Read more →TPSTTempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer
Data Reported at the 2021 Society for Immunotherapy of Cancer Annual Meeting SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combin
Read more →TPSTInvestor Contacts Sylvia Wheeler Wheelhouse Life Science Advisors swheeler wheelhouselsa.com Aljanae Reynolds Wheelhouse Life Science Advisors areynolds wheelhouselsa.com
Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights First patients dosed in first line, randomized, global Phase 1b 2 hepatocellular carcinoma ( HCC ) study of TPST-1120 combination regimen, in collaboration with F. Hoffmann La Roche Exclusiv
Read more →TPSTTempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights
First patients dosed in first line, randomized, global Phase 1b/2 hepatocellular carcinoma (“HCC”) study of TPST-1120 combination regimen, in collaboration with F. Hoffmann La Roche Exclusive rights to novel oncology target in-licensed from the lab of Russell Vance, Ph.D., at th
Read more →TPSTTempest to Present at Two Upcoming Investor Conferences in November
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that managemen
Read more →TPSTTempest Further Bolsters Patent Portfolio with Issuance of Multiple Patents for TPST-1495
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, announced that the U.S. Patent
Read more →TPSTTempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance
Read more →TPSTTempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the first pat
Read more →TPSTTempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target
• Russell Vance, PhD joins Tempest Advisory Board SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune
Read more →TPSTTempest to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that manageme
Read more →TPSTTempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights Closed merger transaction resulting in public listing (TPST) Closed $30M PIPE, extending runway into Q1 23 Advancing TPST-1495 and T
Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights South San Francisco, CA, August 12, 2021 Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both ta
Read more →TPST▲ +8.1%on this newsshared move
Tempest Announces Appointment of Ronit Simantov, M.D. to its Board of Directors
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced th
Read more →TPSTTEMPEST S BUSINESS Overview Tempest is a clinical-stage oncology company focused on leveraging its deep scientific understanding of cancer biology and medicinal chemistry to develop and advance novel, orally available th
Tempest is a clinical-stage oncology company focused on leveraging its deep scientific understanding of cancer biology and medicinal chemistry to develop and advance novel, orally available therapies for the treatment of solid tumors. Tempest s philosophy is to build a company b
Read more →TPSTTempest to Participate in William Blair 2021 Biotech Focus Conference
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Sam Whiti
Read more →TPSTTempest Announces Appointment of Christine Pellizzari to its Board of Directors
SOUTH SAN FRANCISCO, July 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the appoin
Read more →TPSTTempest Closes Merger with Millendo and Completes PIPE Financing South San Francisco, CA
Tempest Closes Merger with Millendo and Completes PIPE Financing South San Francisco, CA, June 28, 2021 Tempest Therapeutics, Inc. (Nasdaq: TPST) ( Tempest ), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and imm
Read more →TPSTTempest and Millendo Announce Stockholder Approval of Merger Tempest to Trade on Nasdaq Public Markets Under Ticker TPST South San Francisco, CA, and Ann Arbor, Mich.
Tempest and Millendo Announce Stockholder Approval of Merger South San Francisco, CA, and Ann Arbor, Mich. June 22, 2021 Tempest Therapeutics, Inc. ( Tempest ), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and i
Read more →TPSTTempest Therapeutics to Present at the Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated mechanisms, today announced that management will be presenting at the
Read more →TPSTTempest and Millendo Announce Proposed Merger Agreement - Transaction to advance Tempest's targeted oncology pipeline - - Concurrent $30M PIPE financing expected to close with merger - - Companies to host conference call
Tempest and Millendo Announce Proposed Merger - Transaction to advance Tempest's targeted oncology pipeline - - Concurrent $30M PIPE financing expected to - Companies to host conference call today at South San Francisco, CA, and Ann Arbor, Mich. March 29, 2021 -Tempest Ther
Read more →TPSTTempest Therapeutics to Present at the Solebury Trout/Credit Suisse/Cooley Private Company Showcase
SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated mechanisms, today announced that management will be presenting at t
Read more →TPSTTempest Therapeutics Announces Clinical Collaboration with Roche to Advance TPST-1120 into a Randomized Combination Study in First-line Hepatocellular Carcinoma
SOUTH SAN FRANCISCO, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated mechanisms, today announced a clinical collaboration agreement with
Read more →TPSTTempest Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated mechanisms, today announced that Tom Dubensky, Ph.D., chief executiv
Read more →TPSTTempest Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated mechanisms, today announced that Tom Dubensky, Ph.D., chief executiv
Read more →TPSTMillendo Therapeutics Provides Pipeline and Business Update - Further investment in MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist, not planned following initial review of data from Phase 1 clinical study -
Millendo Therapeutics Provides Pipeline - Further investment in MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist, not planned following initial review of data from Phase 1 clinical study - - Company exploring expanded range of strategic alternatives to maximize i
Read more →TPSTMillendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist - First subject dosed with MLE-301, for the treatment of vasomotor symptoms (VMS) in menopausal women -
Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist - First subject dosed with MLE-301, for the treatment of vasomotor symptoms (VMS) in menopausal women - - Phase 1 study will evaluate safety, pharmacokinetics and
Read more →TPSTTempest Therapeutics to Present at Two Investor Conferences in August
SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated mechanisms, today announced that management will present at the foll
Read more →TPSTMillendo Therapeutics Provides Corporate and Pipeline Update - MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist, advancing with first-in-human trials expected to initiate in 3Q20 - - Further investment in nev
Millendo Therapeutics Provides Corporate - MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist, advancing with first-in-human trials expected to initiate in 3Q20 - - Further investment in nevanimibe for congenital adrenal hyperplasia (CAH) not planned following inter
Read more →TPSTTempest Therapeutics Announces First Patient Dosed With the Combination of TPST-1120 Plus Nivolumab in a Phase 1 Study in Patients With Advanced Solid Tumors
Combination regimen will treat patients with cholangiocarcinoma, liver and kidney cancers First step in broader combination strategy given TPST-1120’s novel mechanism of action SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical
Read more →TPSTTempest Therapeutics Announces First Patient Dosed in TPST-1495 Clinical Study: Dual EP2/4 Antagonist Targeting Solid Tumors
SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated mechanisms, today announced the first patient dosed in the Phase 1 cl
Read more →TPSTMillendo Therapeutics Announces Topline Results for Pivotal Phase 2b Study of Livoletide in Patients with Prader-Willi Syndrome (PWS) - Livoletide did not achieve statistically significant improvement in primary endpoint
Therapeutics Announces Topline Results for Pivotal Phase 2b Study of Livoletide in Patients with Prader-Willi Syndrome (PWS) - Livoletide did not achieve statistically significant improvement in primary endpoint of change in hyperphagia and food-related behaviors relative to pl
Read more →TPSTTempest Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing therapeutics that combine both precision and immune-mediated mechanisms, announced today that Tom Dubensky, Ph.D., chief executive officer of Te
Read more →TPSTMillendo Therapeutics Appoints Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer - Company also provides update on timeline for pivotal ZEPHYR study
Therapeutics Appoints Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer - Company also provides update on timeline for pivotal ZEPHYR study - ANN ARBOR, Mich., February 10, 2020 - Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company prim
Read more →TPSTTempest Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPST-1495 and Welcomes New Investors
TPST-1495 is a selective dual antagonist of both EP2 and EP4 prostaglandin receptors Lyfe Capital and Rock Springs Capital Management join investor syndicate SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology com
Read more →TPSTCorporate Presentation January 2020 Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking stateme
Statement Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the S
Read more →TPSTGeoff Nichol Appointed to Millendo Therapeutics Board of Directors
Geoff Nichol Appointed to Millendo Therapeutics ANN ARBOR, Mich., December 19, 2019 - Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet ne
Read more →TPSTMillendo Therapeutics Announces Proposed Public Offering of Common Stock
Millendo Therapeutics Announces Proposed Public Offering of Common Stock ANN ARBOR, MICH., December 4, 2019 - Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, today announce
Read more →TPSTTempest Therapeutics’ Oncology Programs Presented at Society of Immunotherapy for Cancer Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing a broad portfolio of first-in-class small molecule therapeutics that combine both precision and immune-mediated mechanisms, today announced
Read more →TPSTTempest Therapeutics Names Biopharmaceutical Executive Stephen Brady as President and Chief Operating Officer
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing a diverse portfolio of first-in-class small molecules targeting cancer, today announced that Stephen Brady has been appointed president and
Read more →TPSTTempest Therapeutics Announces Multiple Presentations at Upcoming SITC 34th Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing a broad portfolio of first-in-class small molecules targeting diverse cancers, today announced that it will have two poster presentations a
Read more →TPSTMillendo Therapeutics Announces Departure of Chief Medical Officer
Millendo Therapeutics Announces Departure of Chief Medical Officer ANN ARBOR, Mich., June 18, 2019 Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that Pharis Mohide
Read more →TPSTMillendo Reports Full Year 2018 Operating and Financial Results --Initiated ZEPHYR, a pivotal Phase 2b/3 clinical study of livoletide for patients with Prader-Willi syndrome (PWS), in 1Q19-- --Topline data from Phase 2b
Millendo Reports Full Year 2018 Operating and Financial Results --Initiated ZEPHYR, a pivotal Phase 2b/3 clinical study of livoletide for patients with Prader-Willi syndrome (PWS), in 1Q19-- --Topline data from Phase 2b Portion of ZEPHYR and Phase 2b clinical study of nevanimib
Read more →TPSTPresentation to Lorem Ipsum Dolor May 2018 Corporate Presentation March 2019 2 Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not hi
Arlt, Endocrine Research, 2010 2. Jenkin-Jones, European Journal of Endocrinology, 2018 3. Hagenfeldt, Human Reproduction, 2008 4. Finkielstain, Endocrine Care, 2012 5. Falhammar, European Journal of Endocrinology, 2014 CHILDHOOD TEEN ADULT Hormonal imbalance from under or overtr
Read more →TPSTMillendo Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Ann Arbor, Michigan (
Millendo Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Ann Arbor, Michigan (January 17, 2019) Millendo Therapeutics, Inc. ( Millendo or the Company ) (NASDAQ: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan
Read more →TPSTPresentation to Lorem Ipsum Dolor May 2018 Corporate Presentation January 2019 2 Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not
Presentation to Lorem Ipsum Dolor May 2018 Corporate Presentation January 2019 2 Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the
Read more →TPSTMillendo Therapeutics Announces Successful Merger Completion Completion of Merger with OvaScience Shares of Combined Company to Commence Trading on the Nasdaq Capital Market Under New Symbol MLND on Monday, December 10th
Millendo Therapeutics Announces Successful Merger Completion Completion of Merger with OvaScience Shares of Combined Company to Commence Trading on the Nasdaq Capital Market Under New Symbol MLND on Monday, December 10th, 2018 Proceeds of $85.4 Million to Fund Orphan Endocrin
Read more →TPSTOvaScience and Millendo Therapeutics Provide Update on Merger Agreement and Financing New Commitment by Great Point Partners Brings Proceeds of Transactions to $87 Million Current OvaScience Shareholders to Benefit from
OvaScience and Millendo Therapeutics Provide Update on Merger Agreement and Financing New Commitment by Great Point Partners Brings Proceeds of Transactions to $87 Million Current OvaScience Shareholders to Benefit from Improved Exchange Ratio WALTHAM, Mass. and ANN ARBOR, Mic
Read more →TPSTOvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company Transaction to Advance Millendo s Compelling Pipeline of Late-Stage Programs for Orphan Endocrine Diseases Including P
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company Transaction to Advance Millendo s Compelling Pipeline of Late-Stage Programs for Orphan Endocrine Diseases Including Prader-Willi Syndrome Companies to Host Conference Call to
Read more →TPSTOvaScience Reports First Quarter 2018 Financial Results and Provides Business Update
OvaScience Reports First Quarter 2018 Financial Results and Provides Business Update WALTHAM, Mass., May 3, 2018 OvaScienceSM (Nasdaq:OVAS), a company focused on the development of new treatment options for women and couples struggling with infertility, today reported financial
Read more →TPSTOvaScience Reports Fourth Quarter and Year-End 2017 Financial Results Initial Data from First 20 Patients in Phase 1 Clinical Trial of OvaPrime Indicates Safety and Tolerability; Conducting Additional Preclinical Studies
OvaScience Reports Fourth Quarter and Year-End 2017 Financial Results Initial Data from First 20 Patients in Phase 1 Clinical Trial of OvaPrime Indicates Safety and Tolerability; Conducting Additional Preclinical Studies to Optimize Proposed Phase 1b/2a Clinical Trial Appointed
Read more →TPSTCorporate Presentation January 2018 Forward-Looking Statements This presentation includes forward-looking statements about the Company's plans for the OvaPrimeSM treatment, the OvaTureSM treatment and the AUGMENTSM treat
Corporate Presentation January 2018 Forward-Looking Statements This presentation includes forward-looking statements about the Company's plans for the OvaPrimeSM treatment, the OvaTureSM treatment and the AUGMENTSM treatment, including forward looking statements relating to: the
Read more →TPSTOvaScience SM Announces Corporate Update Reporting Safety Data from First 20 Patients in Phase 1 Study of the OvaPrime SM Treatment; Advancing OvaPrime into Phase 1b/2a Multi-Center Trial James Lillie, Ph.D.
OvaScienceSM Announces Corporate Update Reporting Safety Data from First 20 Patients in Phase 1 Study of the OvaPrimeSM Treatment; Advancing OvaPrime into Phase 1b/2a Multi-Center Trial James Lillie, Ph.D., Joining as Chief Scientific Officer to Lead Ongoing Preclinical Researc
Read more →TPSTOvaScience Reports Third Quarter 2017 Financial Results Initial Safety Data from First 20 Patients in OvaPrime SM Clinical Trial Expected by Year-End Granted Exclusive License to IVF Japan Group to Offer the AUGMENT SM T
OvaScience Reports Third Quarter 2017 Financial Results Initial Safety Data from First 20 Patients in OvaPrimeSM Clinical Trial Expected by Year-End Granted Exclusive License to IVF Japan Group to Offer the AUGMENTSM Treatment in Japan Conference Call Today at 4:30 p.m. ET WA
Read more →TPSTOvaScience Reports Second Quarter 2017 Financial Results Fertilization of Bovine EggPC Cell-Derived Egg in OvaTure Program on Track for Year-End Completed Target Enrollment in OvaPrime Clinical Safety Study;
OvaScience Reports Second Quarter 2017 Financial Results Fertilization of Bovine EggPC Cell-Derived Egg in OvaTure Program on Track for Year-End Completed Target Enrollment in OvaPrime Clinical Safety Study; Expect to Announce Initial Safety Data in First 20 Patients by Year-E
Read more →TPSTOvaScience Appoints Christopher Kroeger, M.D., M.B.A., as Chief Executive Officer Dr. Kroeger s Combined Business and Medical Experience Ideally Suited to Drive Company s OvaTure and OvaPrime-Focused Strateg
OvaScience Appoints Christopher Kroeger, M.D., M.B.A., as Chief Executive Officer Dr. Kroeger s Combined Business and Medical Experience Ideally Suited to Drive Company s OvaTure and OvaPrime-Focused Strategy Company Restructures Organization to Align with R&D Efforts and Exten
Read more →TPSTOvaScience Reports First Quarter 2017 Financial Results Fertilization of Bovine EggPC Cell-Derived Egg in OvaTure Program on Track for Year-End OvaPrime Clinical Trial Progressing Toward Year-End Initial Rea
OvaScience Reports First Quarter 2017 Financial Results Fertilization of Bovine EggPC Cell-Derived Egg in OvaTure Program on Track for Year-End OvaPrime Clinical Trial Progressing Toward Year-End Initial Readout Robust Financial Position Supports Corporate Strategy into 1Q19
Read more →TPSTOvaScience Reports Fourth Quarter and Year-End 2016 Financial Results OvaTure Program On Track to Successfully Fertilize Bovine Eggs First 50 Patients Enrolled in OvaPrime Clinical Trial Robust Cash Position
OvaScience Reports Fourth Quarter and Year-End 2016 Financial Results OvaTure Program On Track to Successfully Fertilize Bovine Eggs First 50 Patients Enrolled in OvaPrime Clinical Trial Robust Cash Position Expected to Support Operations into Q1 2019 Conference Call Today at
Read more →TPSTto our current report on Form 8-K filed with the Securities and Exchange Commission on
OvaScience Announces Business Update Maintaining AUGMENT Commercial Footprint; Increasing Focus on OvaPrime and OvaTure Improving Cost Structure Through Corporate Restructuring; Extending Cash Chief Executive Officer Harald Stock, Ph.D., Hired to Lead Commercial Expansion, W
Read more →TPSTHarald Stock, Ph.D. Commences Role as President and Chief Executive Officer of OvaScience Begins Role with Strategic Focus on Accelerating Access in Key Markets; Increasing Patient Engagement; and Building A
Harald Stock, Ph.D. Commences Role as President and Chief Executive Officer of OvaScience Begins Role with Strategic Focus on Accelerating Access in Key Markets; Increasing Patient Engagement; and Building Additional Real World Data WALTHAM, Mass., July 1, 2016 OvaScienceSM (NA
Read more →TPSTOvaScience Announces Pricing of Public Offering of Common Stock
OvaScience Announces Pricing of Public Offering of Common Stock WALTHAM, Mass., May 26, 2016 OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it has priced its previ
Read more →TPSTOvaScience Announces Proposed Public Offering of Common Stock
OvaScience Announces Proposed Public Offering of Common Stock WALTHAM, Mass., May 25, 2016 OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it has commenced an under
Read more →TPSTOvaScience Reports First Quarter 2016 Financial Results AUGMENT treatment gains traction in growing fertility market and Company expands access internationally New research supports AUG
OvaScience Reports First Quarter 2016 Financial Results AUGMENT treatment gains traction in growing fertility market and Company expands access internationally New research supports AUGMENT and pipeline treatments WALTHAM, Mass., May 5, 2016 OvaScienceSM (NASDAQ: OVAS), a glob
Read more →TPSTOvaScience Reports Fourth Quarter and Year-End 2015 Financial Results Harald Stock, Ph.D., Appointed as CEO-Elect, Paul Chapman Appointed as COO to Expand Global Commercial and Operatio
OvaScience Reports Fourth Quarter and Year-End 2015 Financial Results Harald Stock, Ph.D., Appointed as CEO-Elect, Paul Chapman Appointed as COO to Expand Global Commercial and Operational Expertise Egg Allocation Study Commenced in Spain Access to the AUGMENTSM Treatment Expa
Read more →TPSTOvaScience Names Harald F. Stock Chief Executive Officer-Elect Industry Veteran Brings Proven, Global Commercial Expertise Michelle Dipp Appointed Executive Chairman of the Board of Directors
OvaScience Names Harald F. Stock Chief Executive Officer-Elect Industry Veteran Brings Proven, Global Commercial Expertise Michelle Dipp Appointed Executive Chairman of the Board of Directors WALTHAM, Mass. Jan. 6, 2016 OvaScienceSM (NASDAQ: OVAS), a global fertility company f
Read more →TPSTOvaScience Provides Business Update and Outlines 2015 Corporate Progress - Company Achieves 2015 OvaPrime and OvaTure Treatment Goals
OvaScience Provides Business Update and Outlines 2015 Corporate Progress - Company Achieves 2015 OvaPrime and OvaTure Treatment Goals - WALTHAM, Mass., December 7, 2015 OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commerciali
Read more →TPSTOvaScience Reports Third Quarter 2015 Financial Results
OvaScience Reports Third Quarter 2015 Financial Results CAMBRIDGE, Mass., November 5, 2015 OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported third quarter 2015 financial re
Read more →TPSTOvaScience Provides Update on Corporate Goal for AUGMENT Treatment
OvaScience Provides Update on Corporate Goal for AUGMENT Treatment CAMBRIDGE, Mass., September 28, 2015 OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that the Company
Read more →TPSTOvaScience Reports Second Quarter 2015 Financial Results - Healthy Babies Born with AUGMENT SM Fertility Treatment; IVF Clinics in New International Regions Offer AUGMENT Treatment - -
OvaScience Reports Second Quarter 2015 Financial Results - Healthy Babies Born with AUGMENTSM Fertility Treatment; IVF Clinics in New International Regions Offer AUGMENT Treatment - - 2015 Plans for OvaPrime and OvaTure Treatments on Track - CAMBRIDGE, Mass., August 10, 2015 O
Read more →TPSTOvaScience Welcomes John Howe, M.D., Former President and CEO of Project HOPE, to Board of Directors
OvaScience Welcomes John Howe, M.D., Former President and CEO of Project HOPE, to Board of Directors CAMBRIDGE, Mass., June 5, 2015 - OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, ann
Read more →TPSTOvaScience Reports First Quarter 2015 Financial Results
OvaScience Reports First Quarter 2015 Financial Results CAMBRIDGE, Mass., May 11, 2015 OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported first quarter 2015 financial result
Read more →TPSTOvaScience Welcomes John Sexton, President of New York University, to Board of Directors
OvaScience Welcomes John Sexton, President of New York University, to CAMBRIDGE, Mass., April 30, 2015 OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today the appointment of
Read more →TPSTOvaScience Reports Fourth Quarter and Year End 2014 Financial Results
OvaScience Reports Fourth Quarter and Year End 2014 Financial Results CAMBRIDGE, Mass., March 16, 2015 OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported fourth quarter and
Read more →TPSTfor the purpose of incorporating the information set forth herein by reference into the registration statement on Form S-3 (File No. 333-200040) that was filed by the registrant with the Securities and Exchange Commissio
The registrant is filing this Exhibit 99.1 for the purpose of incorporating the information set forth herein by reference into the registration statement on Form S-3 (File No. 333-200040) that was filed by the registrant with the Securities and Exchange Commission on November 10,
Read more →TPSTOvaScience Advances All Three Fertility Treatment Options - AUGMENT Treatment Available in Four International Regions - - OvaPrime Treatment to be Introduced into Select International I
OvaScience Advances All Three Fertility Treatment Options - AUGMENT Treatment Available in Four International Regions - - OvaPrime Treatment to be Introduced into Select International IVF Clinics by the End of 2015 - - OvaTure Treatment, a Potential Hormone-Free Fertility Opti
Read more →TPSTOvaScience Strengthens Management Team to Support Expanding Global Operations - Promotes Arthur Tzianabos, Ph.D., to President; Appoints New Head of Commercial
OvaScience Strengthens Management Team to Support Expanding - Promotes Arthur Tzianabos, Ph.D., to President; Appoints New Head of Commercial - CAMBRIDGE, Mass., December 11, 2014 OvaScienceSM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development
Read more →TPSTOvaScience Reports Third Quarter 2014 Financial Results - Company Ahead of Schedule in Achieving Key 2014 AUGMENT SM Treatment Goal
OvaScience Reports Third Quarter 2014 Financial Results - Company Ahead of Schedule in Achieving Key 2014 AUGMENTSM Treatment Goal - CAMBRIDGE, Mass., November 10, 2014 OvaScienceSM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commerc
Read more →TPSTOvaScience Appoints Jeffrey Young to Chief Financial Officer - Reports Inducement Option Grant under NASDAQ Rule 5635(c)(4)
OvaScience Appoints Jeffrey Young to Chief Financial Officer - Reports Inducement Option Grant under NASDAQ Rule 5635(c)(4) - CAMBRIDGE, Mass., September 18, 2014 OvaScienceSM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercializa
Read more →TPSTOvaScience Reports Second Quarter 2014 Financial Results - AUGMENT SM Treatment Available in Three International Regions; Company More than Halfway Toward Goal of 40 AUGMENT Cycles in 2
OvaScience Reports Second Quarter 2014 Financial Results - AUGMENTSM Treatment Available in Three International Regions; Company More than Halfway Toward Goal of 40 AUGMENT Cycles in 2014 - CAMBRIDGE, Mass., August 7, 2014 OvaScienceSM (NASDAQ: OVAS), a global life sciences com
Read more →TPSTOvaScience Reports First Quarter 2014 Financial Results Company Commenced International Launch of
News Release FOR IMMEDIATE RELEASE OvaScience Reports First Quarter 2014 Financial Results Company Commenced International Launch of AUGMENTSM CAMBRIDGE, Mass., May 8, 2014 OvaScienceSM, (NASDAQ: OVAS), a global life sciences company focused on the discovery, development a
Read more →TPSTOvaScience Announces Exercise of Over-Allotment Option in Public Offering of Common Stock Company Management and Directors Establish Stock Purchase Plans
OvaScience Announces Exercise of Over-Allotment Option in Public Offering of Common Stock Company Management and Directors Establish Stock Purchase Plans CAMBRIDGE, Mass., March 18, 2014 OvaScienceSM, (NASDAQ: OVAS), a global life sciences company focused on the discovery, deve
Read more →TPSTfor the purpose of incorporating the information set forth herein by reference into the registration statement on Form S-3 (File No. 333-190939) that was filed by the registrant with the Securities and Exchange Commissio
The registrant is filing this Exhibit 99.1 for the purpose of incorporating the information set forth herein by reference into the registration statement on Form S-3 (File No. 333-190939) that was filed by the registrant with the Securities and Exchange Commission on August 30, 2
Read more →TPSTOvaScience Reports Fourth Quarter and Year End 2013 Financial Results
OvaScience Reports Fourth Quarter and Year End 2013 Financial Results CAMBRIDGE, Mass., February 27, 2014 OvaScienceSM, (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported fourth q
Read more →TPSTOvaScience Provides Update on Pipeline Advancements and Commercial Plans - New potential fertility treatment OvaPrime SM to launch in 2015
OvaScience Provides Update on Pipeline Advancements and Commercial Plans - New potential fertility treatment OvaPrimeSM to launch in 2015 - CAMBRIDGE, Mass., January 13, 2014 OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commerc
Read more →TPSTOvaScience Announces Global Healthcare Strategist Marc Kozin Joins Company s Board of Directors
OvaScience Announces Global Healthcare Strategist Marc Kozin Joins Company s Board of Directors CAMBRIDGE, Mass., January 10, 2014 OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility,
Read more →TPSTOvaScience Appoints David Stern to Executive Vice President, Global Commercial Operations
OvaScience Appoints David Stern to Executive Vice President, Global Commercial Operations CAMBRIDGE, Mass., January 9, 2014 OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announ
Read more →TPSTOvaScience and Intrexon Collaborate to Accelerate Development of OvaScience s OvaTure SM Technology for Infertility Treatments Companies also Form Joint Venture to Develop Applications to Prevent Inherited Human Diseases
OvaScience and Intrexon Collaborate to Accelerate Development of OvaScience s OvaTureSM Technology for Infertility Treatments Companies also Form Joint Venture to Develop Applications to Prevent Inherited Human Diseases and Improve Animal Health Cambridge, MA and Germantown, M
Read more →TPSTOvaScience Reports Third Quarter Fiscal 2013 Financial Results
OvaScience Reports Third Quarter Fiscal 2013 Financial Results CAMBRIDGE, Mass., November 13, 2013 OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today reported financial result
Read more →TPSTOvaScience Provides Update on
OvaScience Provides Update on AUGMENTSM CAMBRIDGE, Mass., September 10, 2013 OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today provided a regulatory, manufacturing and intern
Read more →TPSTOvaScience Reports Second Quarter Fiscal 2013 Financial Results
OvaScience Reports Second Quarter Fiscal 2013 Financial Results CAMBRIDGE, Mass., August 13, 2013 OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today reported financial results
Read more →TPSTOvaScience Appoints Arthur Tzianabos, Ph.D., to Chief Scientific Officer
OvaScience Appoints Arthur Tzianabos, Ph.D., to Chief Scientific Officer CAMBRIDGE, Mass., July 30, 2013 OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appoi
Read more →TPSTOvaScience Appoints Mary Fisher to Company s Board of Directors
OvaScience Appoints Mary Fisher to Company s Board of Directors CAMBRIDGE, Mass., June 11, 2013 OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of
Read more →TPSTOvaScience Reports First Quarter Fiscal 2013 Financial Results
OvaScience Reports First Quarter Fiscal 2013 Financial Results CAMBRIDGE, Mass., May 15, 2013 OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today reported financial results for
Read more →TPSTOvaScience Announces Listing on NASDAQ Under Ticker Symbol
OvaScience Announces Listing on NASDAQ Under Ticker Symbol OVAS CAMBRIDGE, Mass., April 25, 2013 OvaScienceSM, (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that the Company s c
Read more →TPSTOvaScience Announces Agreement for $35 Million Private Placement
OvaScience Announces Agreement for $35 Million Private Placement BOSTON, Mass., March 13, 2013 OvaScience, (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced the execution of a secur
Read more →TPSTOvaScience Reports Fourth Quarter and Year-End 2012 Financial Results
OvaScience Reports Fourth Quarter and Year-End 2012 Financial Results CAMBRIDGE, Mass., February 25, 2013 - OvaScienceSM, (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today reported fourth qua
Read more →TPSTOvaScience Appoints Alison Lawton to Chief Operating Officer
OvaScience Appoints Alison Lawton to Chief Operating Officer CAMBRIDGE, Mass. January 2, 2013 OvaScienceSM, (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of Alis
Read more →TPSTOvaScience Announces Third Quarter Fiscal 2012 Financial Results
OvaScience Announces Third Quarter Fiscal 2012 Financial Results CAMBRIDGE, Mass. November 13, 2012 OvaScienceSM, (OTCBB: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today reported financial result
Read more →Competitive Position
How TPST ranks across every disease it competes inCompetitive Position is a premium feature
See how TPST ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial